Related Experiment Video

Updated: Mar 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent

J L Garcia Lopez1, Barrios J M Rodriguez2, J Puig-Junoy2

  • 1Ramon Y Cajal University Hospital, Alcala University, Madrid, Spain.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|May 21, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Related Experiment Videos

Last Updated: Mar 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

Post-discharge impact and cost-consequence analysis of prehabilitation in high-risk patients undergoing major abdominal surgery: secondary results from a randomised controlled trial.

British journal of anaesthesia·2019

[Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease].

Neurologia (Barcelona, Spain)·2009

Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients.

The European respiratory journal·2003

[Vertical integration and contracting-out in generic hospital services in Spain].

Gaceta sanitaria·2002

[Efficiency in primary health care: a critical review of frontier measures].

Revista espanola de salud publica·2001

[Knowledge, values and politics in health economics].

Gaceta sanitaria·2001

Signaling Demand with Cost-Effectiveness Analysis: A Case Study of PCSK9 Inhibitors.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Cost-Effectiveness and Clinical Utility of a Retinal Cardiovascular AI-Guided Strategy for Statin Initiation: A South Korean Multicenter Prospective Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Sources of the utilities used in paediatric cost-utility analyses in children aged under 5 years, and the methods used in their elicitation: a systematic review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

CONFIRMATORY VALIDATION AND CLUSTER CLASSIFICATION OF THE IRRITABLE BOWEL SYNDROME SYMPTOM SEVERITY SCALE (IBS-SSS).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

The Implementation of NICE Severity Modifier in the Single Technology Appraisal of Mirvetuximab Soravtansine: External Assessment Group Perspective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Cost-Effectiveness Analysis of the Five First-line Treatment Regimens for ALK-positive NSCLC in China: An Economic Evaluation Based on Network Meta-Analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us